Pharma Focus Asia
KP - Sustainable Packaging Solutions

Artiva Biotherapeutics to Construct New Research and Manufacturing Center in Republic of Korea

Introduction:

Artiva Biotherapeutics plans to construct new GMP manufacturing center. The facility will be an addition to the Artiva’s continued research and GMP manufacturing at its partner GC LabCell’s center.

Features:

The new facility designed with 52,000-square-foot will support to develop and provide safe and effective cancer therapies. Moreover, the facility will be in addition to the research and GMP manufacturing at GC LabCell’s state-of-the-art center comprising of research and processing labs and a 50,000-square-foot cell therapy manufacturing facility in the Republic of Korea.

Its features include research and process development laboratories and a multi-suite custom-built Good Manufacturing Practices (GMP) center for the production of NK and CAR-NK therapeutic for the treatment of solid and hematological cancers.

This new facility will help in expanding the leadership position in the evolving field of allogeneic cell therapies.

The construction of the new facility is underway, and expected to be completed in 2022.

Specifications:

NameArtiva Biotherapeutics
TypeNew Construction
Year2022
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelTFS - ODW - The Technology Debate: Single-Use vs. Stainless SteelAsia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 20244th Middle East Pharmacoeconomics and Drug Policy Summit 2024Digital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference
Searching for an end-to-end patient tech solution?